According to a story from proactiveinvestor.com.au, the drug company Pharmaxis Ltd. announced recently that the US Food and Drug Administration (FDA) has granted it Orphan Drug designation. This designation is…
According to a story from Targeted Oncology, findings from a recent phase 1 trial have discovered a new potential treatment for myelofibrosis. The study combined two different drugs: panobinostat (marketed…
Cancer patients often face adverse effects from their treatment. These effects typically need to be addressed by a doctor, whether they're nausea, rashes, or anything else. The issue is that…
The holiday season and end of the year/decade is upon us! As schedules slow down and we begin to reflect, I too began to take stock of the experiences that…
According to a story from Targeted Oncology, recent data suggests that the experimental therapy IMG-7289 could be a useful treatment for patients with myelofibrosis, a rare type of cancer that…
According to a publication from BioSpace, the American Food and Drug Administration (FDA) recently approved the Inrebic (fedratinib) for the treatment of certain myelofibrosis patients. About Myelofibrosis Myelofibrosis is a…
According to a story from BioSpace, CTI BioPharma Corp. has recently concluded an End of Phase 2A meeting with representatives from the US Food and Drug Administration (FDA). This meeting…
According to a story from Newswise, scientists affiliated with the Huntsman Cancer Institute (HCI) of the University of Utah have found in recent lab studies that the experimental drug selinexor…
According to a press release from biotechnology company Forbius (Formation Biologics Inc.), the first patient in the Company's phase 1b trial of experimental myelofibrosis (MF) drug AVID200 has successfully received…
A publication from OncLive recently reported that the FDA has granted the experimental myelofibrosis drug Fedratinib a priority review designation, following Celgene Corporation's submission of a New Drug Application (NDA) to the…
The drug Jakavi (ruxolitinib) is being investigated as a possible treatment for polycythemia vera (PV) and myelofibrosis. Results from studies into this were presented by Novartis at the 23rd Congress of…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
